Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Verrica Pharmaceuticals Q2 Adj. EPS $0.25 Beats $(0.07) Estimate, Sales $12.702M Beat $4.367M Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:02pm
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.07) by 457.14 percent. This is a 180.65 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $12.702 million which beat the analyst consensus estimate of $4.367 million by 190.89 percent. This is a 145.35 percent increase over sales of $5.177 million the same period last year.

Posted In: VRCA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist